For AD patients, cholinesterase inhibitors and the NMDAR low-affinity, uncompetitive antagonist memantine (MEM) are among the few drugs approved by FDA as symptomatic treatments for moderate-to-severe AD, albeit with variable efficacy [20]. Here, BCHE is linked to Alzheimer disease.